CBCS - about us
The Core Facility at Karolinska Institutet is one of six CBCS nodes and a national infrastructure established in 2010 and located in Alfa-5 at SciLifeLab, Campus Solna. CBCS KI provides expertise and instrumentation for assay development and screening (BSL-2 and BSL-3) and enabling chemistry support, including medicinal synthetic and computational chemistry. The facility also accommodates the Compound Center hosting a collection of more than 350 000 small molecules.
The scientists at CBCS have diverse backgrounds from both academia and the pharmaceutical industry and solid experience in assay development, screening and development of bioactive molecules.
Meet our team
Computational Chemistry and Cheminformatics
CBCS has engaged in a partnership with AstraZenecas Open Innovation program to mediate academic collaborators’ access to AstraZeneca’s annotated small molecule compound library.
CBCS is an active partner in the Nordic Chemical Biology Network and subnetworks like the Nordic High content screening community.
Through CBCS, Sweden is a member of EU-OPENSCREEN, the European Infrastructure of Open Screening Platforms for Chemical Biology.
Further, CBCS is an associated partner to the Innovative Medicines Initiative (IMI) program EUbOPEN.